DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Drug Repositioning Benchmarks

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) by APExBIO contains 2,320 clinically approved bioactive compounds, facilitating high-throughput and high-content screening applications (APExBIO product page). The library supports drug repositioning and pharmacological target identification across diverse therapeutic areas, including oncology, neurodegenerative, and metabolic diseases (Meehee Park et al., 2025). Compounds are supplied as pre-dissolved 10 mM DMSO solutions with validated stability profiles. Benchmarking studies using the library have enabled the identification of novel mechanisms, such as the PHF20–YY1 pathway in muscle atrophy and the repurposing of sulfasalazine for sarcopenia. The standardized format and regulatory coverage ensure compatibility with automated workflows and reproducibility in academic and industrial settings.

Biological Rationale

The DiscoveryProbe™ FDA-approved Drug Library was designed to address the need for rapid, systematic evaluation of bioactive compounds in biomedical research. Drug repositioning and target validation are critical for accelerating therapeutic development, particularly in complex diseases lacking effective treatments (Park et al., 2025). The library encompasses drugs with well-defined mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators. Examples include doxorubicin (anticancer, DNA intercalator), metformin (antidiabetic, AMPK activator), and atorvastatin (lipid-lowering, HMG-CoA reductase inhibitor). Such diversity enables the interrogation of multiple signaling pathways, crucial for understanding disease pathology and drug action (related mechanistic review).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This compound collection is curated to represent a comprehensive spectrum of pharmacological mechanisms. Compounds are selected based on regulatory approval from agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or inclusion in recognized pharmacopeias. Mechanistic categories include:

• Receptor agonists and antagonists (e.g., beta-blockers, opioid antagonists)
• Enzyme inhibitors (e.g., kinase, protease, and HDAC inhibitors)
• Ion channel modulators (e.g., calcium, potassium, and sodium channel compounds)
• Signal pathway regulators (e.g., NF-κB, PI3K/mTOR, and Wnt modulators)

Each compound is supplied as a 10 mM solution in DMSO. The collection facilitates direct application in cell-based, biochemical, or phenotypic screening workflows (see HDAC6-targeted screening applications).

Evidence & Benchmarks

• Screening of the DiscoveryProbe™ FDA-approved Drug Library enabled identification of sulfasalazine as a PHF20–YY1 pathway inhibitor in C2C12 myoblasts (IC₅₀ = 24 μM; 37°C, DMEM, 5 days) (Park et al., 2025).
• In mouse models, sulfasalazine administration resulted in enhanced muscle strength and increased muscle mass, demonstrating the library's utility for in vivo target validation (Park et al., 2025).
• Clinical data analysis of IBD patients treated with sulfasalazine showed elevated total psoas index (TPI), indicating muscle mass preservation, reinforcing the translational relevance of library hits (Park et al., 2025).
• Library stability: Compounds stable for 12 months at -20°C, 24 months at -80°C; validated by HPLC purity (>95%) under specified conditions (APExBIO).
• Facilitates robust high-throughput screening; compatibility with 96-well, deep well, and 2D barcoded tube formats supports automation and reproducibility (HTS workflow review).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• Drug repositioning screening in cancer, neurodegenerative, metabolic, and inflammatory disease models
• Pharmacological target identification and pathway mapping
• High-throughput and high-content screening in primary cells, immortalized lines, and organoids
• Polypharmacology and off-target effect profiling ( see polypharmacology study for deeper applications)

Compared to earlier reviews (e.g., HTS workflow), this article details specific in vitro and in vivo benchmarks, including translational endpoints from clinical datasets. Unlike the mechanistic focus in this mechanistic review, this piece presents stability, format, and translational data.

Common Pitfalls or Misconceptions

• Not all compounds are equally active across species or cell types; screening hits require secondary validation.
• The library does not include investigational (non-approved) compounds or natural products outside regulatory scope.
• Some drugs may exert cytotoxic effects at high concentrations not representative of clinical dosing.
• Automated HTS results can be confounded by DMSO sensitivity in some experimental models.
• The library is not designed for direct clinical use or patient administration; for research only.

Workflow Integration & Parameters

The library is delivered as pre-dissolved 10 mM DMSO solutions in 96-well microplates, deep well blocks, or 2D barcoded screw-top tubes. Shipping is on blue ice for evaluation samples, and at room temperature or on blue ice for bulk orders. Upon receipt, compounds should be stored at -20°C (12 months stability) or -80°C (24 months stability). HPLC purity is validated at >95%. The ready-to-screen format supports rapid integration into automated liquid handling platforms for both HTS and HCS applications. Each well and tube is traceable via 2D barcode labeling, reducing sample identification errors (APExBIO).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a rigorously curated, regulatory-grade resource for research in drug repositioning, target identification, and pathway mapping. Benchmark studies—in vitro, in vivo, and with clinical correlates—validate its utility for accelerating discovery in oncology, metabolic, and neurodegenerative disease contexts. Researchers are encouraged to leverage this resource for robust, scalable, and reproducible screening applications. For detailed workflow optimization, see cell-based assay optimization guidance, which this article extends by providing translational and stability evidence.

For more details or to request samples, visit the DiscoveryProbe™ FDA-approved Drug Library product page.